Inventiva Bolsters Its Leadership with Three Key Hires Ahead of Crucial Results
Inventiva announced on Wednesday the recruitment of three new members to its executive team: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Legal Director, and Pamela Herbster as Human Resources Director. These appointments come as the company prepares for the Phase 3 results of lanifibranor expected in the fourth quarter of 2026.
Axel-Sven Malkomes joins Inventiva as Chief Financial Officer, bringing over 30 years of experience in investment banking and corporate leadership. He recently held the CFO position at CureVac and has also served in this role at Cardior and Medigene. Susan Coles becomes Legal Director with more than 25 years of experience in supporting life sciences companies. She previously held this position at Inventiva from 2012 to 2014 and from 2019 to 2021, notably during the company's Nasdaq IPO. Pamela Herbster takes on the role of Human Resources Director with over 25 years of experience in the biopharmaceutical industry, including stints at Sage Therapeutics and Biogen.
Continued Roles and New Responsibilities
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Jean Volatier, who served as Chief Financial Officer and has been with Inventiva since its inception, will take on the role of Executive Vice President of Finance and Corporate Social Responsibility. Nathalie Harroy, who was in charge of Human Resources, will remain at Inventiva and continue her contribution to the organization by leveraging her experience.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
